Introduction {#S0001}
============

In recent years, more and more research results have suggested that the patient-derived tumor xenografts (PDTX) model can be successfully established using immunity-deficient mice by inoculating the resected tumor tissue from the patient during an operation. The tumor model established by this method can better maintain the growth environment of tumor cells, the matrix and fibroblasts between tumor cells, and can also maintain the basic morphology of tumors and the structure of their internal vascular network, making the three-dimensional structure of the whole tumor model highly consistent with that of the tumors in clinical patients.[@CIT0001],[@CIT0002] (The application in gastric cancer and the success rate of establishing the model are introduced to explain the significance of this experiment.) In the current study, NCG mice were selected as the host of the xenotransplantation of human primary gastric cancer to establish an experimental animal model that can be passaged and resuscitated and retain the clinical tissue characteristics of primary tumors that is the PDTX model. Details are reported as follows:

Materials and Methods {#S0002}
=====================

This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the ethics committee of Tianjin Medical University Cancer Institute and Hospital. Written informed consent was obtained from the participants. We confirmed that ethical and legal approval was obtained prior to the commencement of the study, and all experiments were performed following relevant named institutional and national guidelines and regulations.

Experimental Animals {#S0002-S2001}
--------------------

NCG mice were purchased from Nanjing University-Nanjing Institute of Biomedicine, SPF grade, 6--8 weeks old, weighing approximately 20 ± 2 g. All mice were fed in the barrier system, the temperature was 25 ± 2 °C and the humidity was 40--70%. The mice were provided with food and water ad libitum. Before the experiment, all the mice were fed adaptively in the barrier system for 5--7 days.

Reagents and Consumables {#S0002-S2002}
------------------------

The required reagents and consumables included 10% formaldehyde, Leibovitz's L15 tissue preservation solution, double antibodies, surgical equipment, gauze, etc.

Tumor Specimens {#S0002-S2003}
---------------

In the current study, all the tumor tissues originated from the resected tumor tissues of patients in Tianjin Cancer Hospital, there were a total of 20 patients ([Table 1](#T0001){ref-type="table"}). Tumor tissue was removed by a clinical surgeon and immediately placed in a tissue preservation solution and sent to the laboratory, then necrosis and residual blood on the surface of the tumor tissue were removed in the clean bench.Table 1Basic Data of PatientsPatientsSexAgeDiagnosisMethodsTNM StagePathological TypesDifferentiated DegreeFollow-UpPFSA19072Male54Ganstric cancerSurgery (5.9)IIICAdenocarcinoma with signet ring cell carcinomaPoorly differentiatedStable disease18mA19078\*Male51Ganstric cancerSurgery (6.6)IIIBAdenocarcinoma with signet ring cell carcinomaPoorly differentiatedProgressive disease10m peritoneal metastasisA19080Male76Ganstric cancerSurgery (6.7)IIBAdenocarcinomaModerately-to-poorly differentiatedStable disease16m0501001Female40Ganstric cancerSurgery (6.14)IIIASignet ring cell carcinoma with diffuse poorly differentiated adenocarcinomaPoorly differentiatedStable disease17m0501002\*Female63Ganstric cancerSurgery (6.19)IIIBMucinous adenocarcinomaPoorly differentiatedProgressive disease6m peritoneum metastasis0501003Male69Ganstric cancerSurgery (6.23)IIBAdenocarcinoma with signet ring cell carcinoma and mucinous adenocarcinomaModerately-to-poorly differentiatedStable disease16m0501004\*Female73Ganstric cancerSurgery (6.23)IIICAdenocarcinoma and signet ring cell carcinomaPoorly differentiatedProgressive disease7 mhepatic metastasis0501005\*Male59Ganstric cancerSurgery (6.23)IIIBAdenocarcinomaPoorly differentiatedStable disease16m0501006\*Female60Ganstric cancerSurgery (6.28)IIICAdenocarcinoma, partially signet ring cell carcinomaPoorly differentiatedProgressive disease3m renal metastasis0501007\*Female74Ganstric cancerSurgery (6.29)IIIAAdenocarcinoma, partially signet ring cell carcinomaPoorly differentiatedProgressive disease10m lymphatic metastasis0501008\*FemaleGanstric cancerSurgeryIIICMucinous adenocarcinoma with signet ring cell carcinomaModerately-to-poorly differentiatedStable disease14m0501009\*Female69Ganstric cancerSurgeryIIIASignet ring cell carcinoma with diffuse poorly differentiated adenocarcinomaPoorly differentiatedStable disease14m0501010\*Male55Ganstric cancerSurgeryIIIBTubular adenocarcinoma with mucinous adenocarcinomaModerately-to-poorly differentiatedStable disease13m0501011\*Female47Ganstric cancerSurgeryIIIASignet-ring cell carcinomaModerately-to-poorly differentiatedStable disease13m0501012\*Female62Ganstric cancerSurgeryIIBMucinous adenocarcinoma with moderately differentiated tubular adenocarcinomaModerately differentiatedStable disease13m0501013\*Male55Ganstric cancerSurgeryIBMediumly-poorly differentiated tubular adenocarcinomaModerately-to-poorly differentiatedStable disease13m0501014\*Male60Ganstric cancerSurgeryIIIBPoorly differentiated adenocarcinomaPoorly differentiatedStable disease13m0501015\*Female63Ganstric cancerSurgeryIVAdenocarcinoma and signet ring cell carcinomaPoorly differentiatedProgressive disease7m peritoneal metastasis0501016Male64Ganstric cancerSurgeryIBTubular adenocarcinomaModerately differentiatedStable disease14m0501017\*Male66Ganstric cancerSurgeryIBAdenocarcinomaModerately differentiatedStable disease14m[^1]

Tumor Transplantation Methods and Passage {#S0002-S2004}
-----------------------------------------

Fresh tumor tissue removed through clinical surgery was placed in a medium containing 1% double-antibody, then a tissue scissor was used to cut the tissue into several small pieces, approximately 2 mm × 2 mm × 2 mm in size. After disinfection and the preparation of skin on both of the sides of the mice's forelimbs, a trocar was used to inject the tumor tissue rapidly into the subcutaneous tissue. The puncture needle was then rotated and removed and a cotton ball was used to clean the oozing of blood on the surface of the mice's skin to prevent biting because of the residual blood. After tumor formation, the length and width of the tumors were measured regularly and the relative tumor volume (relative tumor volume = 0.5× long diameter × short diameter^2^) was calculated twice a week on average. In the current study, the criterion for successful transplantation of a tumor in mice is that the volume of the tumors in a mouse should exceed 60 mm^3^. P2 passage was performed when P1 tumors grew to 500 mm^3^. There were six mice in each group.

Model Monitoring Indicators {#S0002-S2005}
---------------------------

\(1\) Changes in the mental state, activity, diet and hair color of the mice were observed daily. (2) The growth of the local subcutaneously transplanted tumor in the mice of each group was observed and recorded. (3) The tumorigenic rate and mortality rate of the mice in each group were counted. (4) Mice were euthanized, the transplanted tumor was removed, and the histomorphological characteristics of the tumor specimens from the clinical patients and the transplanted tumors of each generation were observed using H&E staining. (5) The expressions of ck8/18, CK7, ki-67, matrix metalloproteinase 9 (MMP-9), epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (Her-2) in the tissues of P0 and P1 immune generation mice were detected by immunohistochemistry.

Pharmacodynamic Detection {#S0002-S2006}
-------------------------

When the average volume of the tumors in P2 mice reached 100--150 mm^3^, the mice were randomly grouped: one control group (no treatment), and 10 treatment groups (according to the situation of the subjects, and their recommended chemotherapeutic drugs and/or regimens for testing, synchronized therapy with the corresponding drugs and/or regimens for corresponding subjects was given, all tested drugs were provided by the patients).After administration, the general condition of the mice was observed and recorded daily, tumor volume was measured, and the weight of the tumor-bearing mice was also measured twice a week. After three weeks of continuous observation, a tumor growth curve and an animal weight change curve were drawn, and a PDTX test report was written.

Statistical Analysis {#S0002-S2007}
--------------------

We used the software program SPSS 20.0 (IBM, Chicago, USA) to conduct the statistical analysis. Continuous variables were expressed as mean± SD. Discontinuous variables were expressed as percentage (%). A value of P\<0.05 was considered statistically significant.

Results {#S0003}
=======

Tumor Formation and Growth of Mice {#S0003-S2001}
----------------------------------

The primary transplantation of tumor specimens to NCG mice was performed in 20 patients. At 4--6 weeks after inoculation, a slightly rigid solid mass protruding from the skin could be seen at the site of the inoculation. As time progressed, the tumor nodules gradually enlarged. When the tumor volume of the mice exceeded 60 mm^3^, it indicated that the model was successfully established. The results of the current study revealed that a total of 15 mice were successfully modeled. The success rate of the primary transplantation was 75%. The tumor formation time was 40--115 days. The growth of P1 generation tumors is shown in [Figure 1](#F0001){ref-type="fig"}.Figure 1The growth curve of P1 generation mice. A total of 15 mice are successfully modeled 4--6 weeks after injection. The success rate of primary transplantation is 75%. The tumor formation time is 40--115 days.

Histopathological Examination of Specimens of Patients and Transplanted Tumors {#S0003-S2002}
------------------------------------------------------------------------------

When the tumor volume in mice increased to 800 mm^3^, the mice were euthanized and the transplanted tumors removed. The results of the current study reveal that the transplanted tumors in the mice were smooth on the surface, round or quasi-round in shape, solid, and slightly hard in texture. The tumors were cut according to the P1 generation inoculation method and re-injected into P2 generation mice. No obvious infiltrations were found in the other organs of the mice. The results of the H&E staining of the specimens of clinical patients and the expressions of ck8/18, CK7, Ki-67 and MMP-9 in tumor tissues are shown in [Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"}. Moreover, the histopathological structure of PDTX mice tumors was basically consistent with that of the corresponding patient.Figure 2The comparison of homogeneity of pathology between P1 generation tumors in PDTX model mice and tumors in the original patients. H&E staining results reveal that the histopathological structure of tumors in clinical patients is basically the same as that in PDTX model mice.Figure 3The expressions of ck8/18, CK7, ki-67 and MMP-9 in P0 and P1 tissues. The expressions of ck8/18, CK7, Ki-67 and MMP-9 are significant in tumor tissues in clinical patients.

Pharmacodynamic Test Results {#S0003-S2003}
----------------------------

The pharmacodynamics test was carried out in 0501011 patients after successful modeling. As shown in [Figure 4](#F0004){ref-type="fig"}, the results revealed that Scheme 6 (gemcitabine) \> Scheme 11 (cisplatin + tegafur) \> Scheme 8 (cisplatin) \> Scheme 3 (irinotecan) \> Scheme 2 (oxaliplatin + tegafur) \> Scheme 9 (albumin paclitaxel + capecitabine) \> Scheme 7 (albumin paclitaxel). The tumor growth inhibition value (TGI) and relative tumor volume (RTV) of these drugs were listed in the [Table 2](#T0002){ref-type="table"}. When the PDTX model was established, the patient began to receive clinical concurrent adjuvant chemotherapy after the operation, and the treatment regimen was oxaliplatin + tegafur. Because the side effects of tegafur are substantial in clinical treatment, the drugs were adjusted to oxaliplatin + retitroxel (currently, a clinical follow-up is underway).Table 2Anti-Tumor Rate of Different Chemotherapy RegimensNo.Chemotherapy RegimensTGIRTV0Control/1.371Oxaliplatin + tegafur19.0%1.112Irinotecan30.6%0.953Epirubicin−14.0%1.584Olaparib−19.4%1.635Gemcitabine47.6%0.716Albumin paclitaxel2.5%1.367Cisplatin38.7%0.868Albumin paclitaxel + capecitabine17.4%1.129Oxaliplatin−1.3%1.4210Cisplatin + tegafur39.7%0.84 Figure 4The pharmacodynamic test results of patient 0501011 Clinical chemotherapy results reveals that Scheme 6 (gemcitabine) \> Scheme 11 (cisplatin + tegafur) \> Scheme 8 (cisplatin) \> Scheme 3 (irinotecan) \> Scheme 2 (oxaliplatin + tegafur) \> Scheme 9 (albumin paclitaxel + capecitabine) \> Scheme 7 (albumin paclitaxel).

Clinical Follow-Up of Prognosis {#S0003-S2004}
-------------------------------

The duration of the clinical follow-up was 17 months. Follow-up results revealed that, of the 15 patients whose models were successfully established, disease progression during the follow-up period occurred in six patients. Disease in the five patients whose models were unsuccessfully establishedisstable at present. The success rate of the PDTX model correlates significantly with the prognosis of the patient, which is worth further study (p=0.0086, \<0.05). The prognoses of clinical patients during follow-up are shown in [Figure 5](#F0005){ref-type="fig"}.Figure 5The Histopathological examination of abnormal mice. Spleen: The red pulp structure of the spleen almost disappears. There is a large amount of pigmentation in tissues, and a small number of karyokinesis can be observed. Liver: The liver tissue has clear structures. There is a large amount of monocyte infiltration in most of the portal area of the hepatic lobules, sinus and central vein; there is a small amount of dispersive pigmentation in the tissue. Kidney: The kidney tissue has clear structures. There is monocyte infiltration in the interstitium around a few of the glomeruli, and no other pathological changes are found.

Discussion {#S0004}
==========

At present, epidemiological data reveals that the morbidity and mortality of gastric cancer ranks first among malignant digestive system tumors in China. Although at present surgery, radiotherapy and chemotherapy are still the first choices for the treatment of gastric cancer, the results of a large number of studies have revealed that there were significant individual differences in biological characteristics and drug sensitivity of tumor tissues in clinical patients with tumors, even if the same type of cancer has huge individual differences among different patients. At present, the development of new anti-cancer drugs and the selection of clinical chemotherapy are often based on the drug sensitivity test of tumor cells cultured in vitro, genetic testing and in vivo models of the transplantation of passaged tumor cells, but these do not really reflect the individual's sensitivity to chemotherapeutic drugs or targeted drugs, therefore, the predictability was poor.[@CIT0001],[@CIT0002] In recent years, some foreign scholars used a PDTX model for pharmacodynamics tests, which provided a new idea for individualized treatment of clinical cancer patients.

The results of previous studies have revealed that the success rate of PDTX modeling for surgical specimens was 25--40%.[@CIT0003]--[@CIT0005] It was also reported that the success rate of needle aspiration puncture for small cell lung cancer was 75%.[@CIT0006] In the current study, among these 20 patients, a PDTX model was successfully established for 15 patients, making the success rate of modeling 75%, with the PDTX model maintaining the biological characteristics of the primary tumors. The result is consistent with that of previous studies on, gastric cancer, liver cancer, lung cancer, colorectal cancer, melanoma, and esophageal cancer etc. Therefore, a PDTX model is a stable and reliable cancer research model andcan provide a good animal model for cancer studies.[@CIT0007]--[@CIT0009]

In the current study, a mice model was unsuccessfully established for five patients. The main reasons are as follows: 1. accidental death, 2. tumors did not grow, or they grew slowly and then did not meet the criteria, 3. infection. During the process of this experiment, one month after inoculation, for specimens A19078, A19080, 0501006 and 0501007, some mice started to successively develop hair loss and became weak. After examination, no microbial infection was found, inflammatory cell infiltration was found in the portal area of the liver, perivascular area and renal interstitium, vigorous karyokinesis were found in some cells in the spleen, and no obvious pathological changes were found in the ovaries and uterus ([Figure 6](#F0006){ref-type="fig"}). Because the team of this study has carried out immune reconstitution experiments in NCG mice, similar phenomena occurred one month after tail vein injection of peripheral blood mononuclear cell (PBMC), therefore, it was considered that the reason may be related to immune rejection. It is suspected that it is caused by further inflammatory cell infiltration in the inoculated tumor tissue. Its mechanism needs further study.Figure 6The prognoses of clinical patients. Of the 15 patients whose models were successfully established, disease progression during the follow-up period occurred in six patients. Disease in the five patients whose models were unsuccessfully established is stable at present.

The results of this study revealed that the characteristics of blood supply, matrix, growth and necrosis of the transplanted tumors in the mice were consistent with those of human tumors. Therefore, PDTX modeling is likely to be an important and highly homogenous in vivo model. At present, the tissue source for the PDTX model was mainly resected tumor tissue during enlarged surgery. However, many patients with advanced tumors are not suitable for surgical treatment and tumor tissues cannot be obtained from these patients, therefore, the clinical application of PDTX is limited.

In order to confirm that P1 generation tumors have the same proliferation activity and malignant behavior as primary tumors, its proliferation potential and transfer risk are consistent, and mutation sites and gene expressions can be an effective alternative, the expressions of ck8/18, CK7, ki-67, MMP-9, EGFR and Her-2 in P0 and P1 tissues were selected and analyzed. The results revealed that the two types of tissues were highly homogenous. Cytokeratin (CK) is an intermediate fiber; its family consists of highly complex polygenic proteins, and the molecular weight ranges between 40--68 kDa.Up until now, 20 CK proteins (CK1-CK20) have been discovered. An in vitro experiment revealed that, compared with the control cells, various cell lines overexpressing CK8/18, including lung adenocarcinoma, melanocytes and mouse L cell lines, have a higher migration and stronger invasiveness. ki-67 is a relatively positive marker for nuclear proliferation in relation to cell cycle, which only exists in the nucleus of proliferating cells.[@CIT0010] The coding gene is located on chromosome 10 and its expression increases with the progress of cell cycle. In the cell division cycle, it is not expressed in G0 phase, begins to express in G1 phase, increases gradually in S and G2, reaches its peak in M phase, and degrades and disappears rapidly after the end of cell division, therefore it is an important indicator of cell proliferative activity, and widely used to evaluate the proliferation of cancer cells. There have been many studies on the relationship between gastric cancer and Ki-67, but there is still controversy at present. Studies have revealed that the expression of Ki-67 in gastric cancer tissues was closely correlated to the clinicopathology and prognosis of the patients. Tsamandas et al revealed in their studies that ki-67 was correlated to the prognosis of patients with gastric cancer. Kikuyama et al considered that Ki-67 was an independent prognostic factor of patients with gastric cancer. Matrix metalloproteinases (MMPs) are proteolytic enzymes very closely related to invasion and metastasis of tumors. As a matrix, metalloproteinase can degrade basement membrane and extracellular matrix components, and accordingly, promote the infiltration and metastasis of tumors and interstitial angiogenesis. The detection of its expression level plays an important role in the prospective determination of the biological characteristics of tumors and it acts as a prognostic indicator. In the current study,CK8/18 and Ki-67 were highly expressed in all three patients whose models were successfully established, whether in the original tumors or in the PDTX model. The results suggest that tumor tissue has strong invasiveness and metastasis ability. MMP-9 was weakly positive in the model of one patient. Its significance in predicting the prognosis of gastric cancer needs further verification.

In the PDTX study on colorectal cancer published by Samsung Medical Center in South Korea,[@CIT0011] 241 patients with colorectal cancer were analyzed retrospectively. The model of nude mice was established by transplanting surgical samples to investigate the relationship between the success rate of PDTX and clinical prognosis in patients with colorectal cancer. The results revealed that the prognosis of patients whose model was successfully established poorer than that of patients whose model was not successfully established, especially obvious in patients at stage 3, long-term differences could also be seen in patients at stage 4 with metastasis. The prognosis of patients whose model was successfully established was poorer than that of patients whose model was not successfully established. This suggests that PDTX can reflect the invasiveness of tumors and can be used as one of the indicators to predict recurrence and metastasis in the future. In the current study, 1-year follow up results revealed that of the 15 patients whose models were successfully established, disease progression occurred in six patients, while disease in patients with a failed model establishment is currently stable. The success rate of PDTX models was significantly correlated with the prognosis of patients, which is worth further study.

In our study, the pharmacodynamics test revealed that Scheme 6 (gemcitabine) \> Scheme 11 (cisplatin + tegafur) \> Scheme 8 (cisplatin) \> Scheme 3 (irinotecan) \> Scheme 2 (oxaliplatin + tegafur) \> Scheme 9 (albumin paclitaxel + capecitabine) \> Scheme 7 (albumin paclitaxel). However, the specific differences among these kinds of chemotherapy regimens should be further research in the future.

PDTX models can better preserve the biological characteristics of primary tumor tissues and their response to drugs.[@CIT0012]--[@CIT0016] PDTX models can be used as a substitute for cancer patients in clinical practice and may be suitable for clinical pharmacodynamic screening and new drug development. It has a wide application prospect.[@CIT0017]
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[^1]: **Note:** \*P1 modeling successfully.
